Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;271(3):1320-1330.
doi: 10.1007/s00415-023-12068-4. Epub 2023 Nov 18.

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy

Alexandre Guérémy  1 , José Boucraut  2   3 , John Boudjarane  4 , Aude-Marie Grapperon  1 , Etienne Fortanier  1 , Laure Farnault  5   6 , Jean Gabert  7   8 , Frédéric Vely  2   8 , Romaric Lacroix  9   10 , Ludivine Kouton  1 , Shahram Attarian  1 , Emilien Delmont  11
Affiliations
Free article

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy

Alexandre Guérémy et al. J Neurol. 2024 Mar.
Free article

Abstract

Introduction: Anti-MAG neuropathies are associated with an IgM monoclonal gammopathy of undetermined significance (MGUS) or with a malignant haemopathy. Our objective was to determine whether the presence of a haemopathy or somatic mutations of MYD88 and CXCR4 genes influences disease presentation and response to rituximab (RTX).

Methods: We included 79 patients (mean age 74 years, disease duration 9.68 years) who had a bone marrow aspiration with morphologic and immunophenotypic analysis. MYD88L265P and CXCR4 mutations were analysed in peripheral B cells. Information collected included: inflammatory neuropathy cause and treatment sensory sum score (ISS), MRC testing, overall neuropathy limitation scale (ONLS), Rash-built Overall Disability Score (RODS), ataxia score, anti-MAG titres, peak IgM dosage, neurofilament light chain levels, motor and sensory amplitudes, motor unit index (MUNIX) and motor unit size index (MUSIX) sum scores. Efficacy of RTX was evaluated at 12 months in 26 patients.

Results: Malignant haematological disorders were discovered in 17 patients (22%): 13 Waldenstrom macroglobulinemia, 3 marginal zone lymphoma and one mantle cell lymphoma. MYD88L265P mutation was detected in 29/60 (48%) patients and CXCR4 in 1 single patient. Disease severity, biological and electrophysiological data and response to RTX were comparable in patients with MGUS/lymphoma and patients with/without MYD88L265P mutation. ISS was lower and MUSIX higher in patients improved by RTX.

Conclusions: MYD88L265P mutation and underlying haemopathies are not predictive of a more severe disease. However, in cases of resistant and progressive neuropathy, they provide an opportunity to prescribe newly available drugs such as Bruton tyrosine kinase inhibitors.

Keywords: Anti-MAG; Biological; Clinical; Electrophysiological; Haemopathy; MYD88.

PubMed Disclaimer

References

    1. Svahn J, Petiot P, Antoine JC, Vial C, Delmont E, Viala K, Steck AJ, Magot A, Cauquil C, Zarea A, Echaniz-Laguna A, IancuFerfoglia R, Gueguen A, Magy L, Léger JM, Kuntzer T, Ferraud K, Lacour A, Camdessanché JP, Francophone Anti-MAG cohort Group (2018) Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89(5):499–505. https://doi.org/10.1136/jnnp-2017-316715 - DOI - PubMed
    1. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123(Pt 4):710–717. https://doi.org/10.1093/brain/123.4.710 - DOI - PubMed
    1. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, RIMAG Study Group (France and Switzerland) (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80(24):2217–2225. https://doi.org/10.1212/WNL.0b013e318296e92b - DOI - PubMed - PMC
    1. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65(3):286–293. https://doi.org/10.1002/ana.21577 - DOI - PubMed
    1. Steck AJ (2021) Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol 361:577725. https://doi.org/10.1016/j.jneuroim.2021.577725 - DOI - PubMed

MeSH terms